Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma

BACKGROUND: Sorafenib is the only drug approved for the treatment of hepatocellular carcinoma (HCC). The bioenergetic propensity of cancer cells has been correlated to anticancer drug resistance, but such correlation is unclear in sorafenib resistance of HCC. METHODS: Six sorafenib-naive HCC cell li...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Shen, Y-C, Ou, D-L, Hsu, C, Lin, K-L, Chang, C-Y, Lin, C-Y, Liu, S-H, Cheng, A-L
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group 2013
Onderwerpen:
Translational Therapeutics
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3553537/
https://ncbi.nlm.nih.gov/pubmed/23257894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.559
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items